Search

Your search keyword '"Qiao, Kai"' showing total 15 results
Start Over Author "Qiao, Kai" Publisher wiley
15 results on '"Qiao, Kai"'

1. Eomesodermin expression in CD4+T‐cells associated with disease progression in amyotrophic lateral sclerosis

Author

Chen, Sheng, primary, Huan, Xiao, additional, Xu, Chun‐Zuan, additional, Luo, Su‐Shan, additional, Zhao, Chong‐Bo, additional, Zhong, Hua‐Hua, additional, Zheng, Xue‐Ying, additional, Qiao, Kai, additional, Dong, Yi, additional, Wang, Ying, additional, Liu, Chang‐Yun, additional, Huang, Hua‐Pin, additional, Chen, Yan, additional, and Zou, Zhang‐Yu, additional

Published
2023
Full Text
View/download PDF

2. Plant‐Derived Biomaterials and Their Potential in Cardiac Tissue Repair

Author

Dai, Yichen, primary, Qiao, Kai, additional, Li, Demin, additional, Isingizwe, Phocas, additional, Liu, Haohao, additional, Liu, Yu, additional, Lim, Khoon, additional, Woodfield, Tim, additional, Liu, Guozhen, additional, Hu, Jinming, additional, Yuan, Jie, additional, Tang, Junnan, additional, and Cui, Xiaolin, additional

Published
2023
Full Text
View/download PDF

15. Long-term and low-dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy.

Author

Zheng Y, Sun C, Zhao Y, Meng Q, Hu J, Qiao K, Sun J, Xi J, Luo S, Lu J, Zhao C, and Lin J

Subjects
Humans, Male, Middle Aged, Female, Aged, Adult, Treatment Outcome, Rituximab administration & dosage, Rituximab adverse effects, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating drug therapy, Immunologic Factors administration & dosage, Immunologic Factors adverse effects
Abstract

Objective: To evaluate the efficacy and safety of a low-dose, long-term rituximab regimen in the treatment of idiopathic CIDP., Methods: This study included 15 CIDP patients treated with rituximab. Patients were administered 600 mg of rituximab intravenously every 6 months. Baseline evaluation was conducted before the initiation of rituximab treatment and subsequent evaluations were conducted 6 months after each rituximab infusion at on-site visits. Clinical improvement was objectively determined by improvement of scale score at least decrease ≥1 INCAT or mRS or increase ≥4 MRC or ≥8 cI-RODS after each infusion compared to baseline evaluation., Results: Fifteen CIDP patients were included and 10 of them were typical CIDP and five were distal CIDP. Nine in 15 (60%) patients after first infusion and three in six (50%) patients after second infusion exhibited significant clinical improvement compared to baseline evaluation. Additionally, rituximab facilitated a reduction or cessation of other medications in 73% of patients at last visit. The safety profile was favorable, with no reported adverse events., Conclusion: Rituximab presents a promising therapeutic option for idiopathic CIDP, offering both efficacy and safety with a low-dose, long-term regimen., (© 2024 Peripheral Nerve Society.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results